"A Double-blind Preferred Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile Dysfunction"

PHASE3CompletedINTERVENTIONAL
Enrollment

611

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

May 31, 2004

Study Completion Date

May 31, 2004

Conditions
Erectile Dysfunction
Interventions
DRUG

Levitra (Vardenafil, BAY38-9456)

10mg Vardenafil for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg Vardenafil or down to 5mg Vardenafil followed by 14 weeks treatment at preferred dose.

DRUG

Placebo

10mg placebo for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg placebo or down to 5mg placebo followed by 14 weeks placebo at preferred dose

Trial Locations (23)

24

Dublin

Dublin

RG7 3SG

Reading

DH1 2QW

Durham

LL18 5UJ

Rhyl

PL4 8QU

Plymouth

NW9 9NH

London

M13 9WL

Manchester

M31 OUH

Manchester

PO3 6AD

Portsmouth

HA6 2RN

Northwood

NR1 3SR

Norwich

BT12 6BA

Belfast

OX7 5AL

Chipping Norton

SY1 1RL

Shrewsbury

CF2 5HW

Cardiff

DN1 2ET

Doncaster

WS14 9JL

Lichfield

G21 3UW

Glasgow

ML3 ODR

Hamilton

ML1 3JX

Motherwell

CV6 4DD

Coventry

LS1 3EX

Leeds

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00661700 - "A Double-blind Preferred Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile Dysfunction" | Biotech Hunter | Biotech Hunter